RxDoctor Payments Data

Ankur Gupta, MD

Interventional Cardiology · Scottsdale, AZNPI 1699930685

Payments from drug & device makers

$28,430in general payments, 2019–2025

Across 116 payments — averaging $245.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$11K
  • Abbott$10K
  • Abiomed$3K
  • Boston Scientific$1K
  • Livanova USA, Inc.$712
  • Novartis$472
  • plus $2K from 13 others

What the payments were for

  • Consulting fees$5,00018%
  • Speaking & faculty fees$13,30047%
  • Travel & lodging$3,90614%
  • Food & beverage$6,22422%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,430 in reported general payments places this provider in the 65th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona

Medicare billing

Part B allowed, 2024
$437,635
Medicare patients
809
Services billed
4,826

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban120$117,800
JardianceEmpagliflozin54$65,196
Repatha SureclickEvolocumab52$42,934
XareltoRivaroxaban26$35,444
EntrestoSacubitril/Valsartan25$26,561
FarxigaDapagliflozin Propanediol12$7,578
Ezetimibe135$4,600
Metoprolol Succinate280$4,074
ClopidogrelClopidogrel Bisulfate254$3,317
Atorvastatin Calcium281$2,921
Rosuvastatin Calcium117$1,830
Carvedilol86$992
Amlodipine Besylate164$970
Chlorthalidone42$816
Amiodarone Hcl27$776

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$36$117,800120 claims
NovartisEntresto$472$26,56125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 223 interventional cardiology providers in Arizona.

Other interventional cardiology in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →